Financial Analysis

Hanmi Pharma (128940.KS) Q1 2026: R&D at 16.6% Narrows Operating Profit 9%

Hanmi Pharmaceutical Q1 2026: Revenue flat at ₩392.9B (+0.5%), operating profit -9.1% to ₩53.6B as R&D hit 16.6% of sales. Net income rose 14.4% to ₩51.1B. Beijing Hanmi's 22% margin cushions results.

OCI Holdings (010060.KS) Q1 2026: Operating Profit Collapses 78% on ₩26.6B TerraSus Maintenance Loss

NC (036570.KS) Q1 2026: Aion 2 Ignites 22x Profit Jump to ₩113B

Hanwha Engine Q1 2026: ₩5.17 trillion backlog and positive free cash flow underpin margin recovery as SEAM acquisition reshapes balance sheet

L&F (066970.KS) Q1 2026: Revenue Doubles, Operating Swing Driven by ₩136.2B Inventory Reversal

Doosan Fuel Cell (336260.KS) Q1 2026: Revenue Surges 45%, Backlog Crashes to ₩30B

Doosan Bobcat Q1 2026: Revenue Rebounds to $1.53B as Net Income Climbs 15%, but Gross Margin Slips 131bp

Coway Q1 2026: Record ₩250.9 Billion Operating Profit Anchored by Rental Subscription Growth

Kakao Pay (377300.KS) Q1 2026: Profit 7x, Finance Turns Profitable

Gaon Cable (000500.KS) Q1 2026: Profit Up 27% as Copper Spike Burns ₩170.9B Cash

Doosan Robotics (454910.KS) Q1 2026: Revenue Nearly Triples as Consolidated Operating Loss Holds at ₩12.1B

Amorepacific (090430.KS) Q1 2026: Domestic Profit Surges 65%, COSRX Overseas Down 18%